Interest in boosting bioavailability has risen as compounds coming through development pipelines have become less soluble. However, improvements to formulation are expected to be gradual.
“I don’t think I have seen a dramatically new approach to this. We will develop them, refine, improve, but perhaps not [make] a quantum leap”, Graham Buckton, CEO of Pharmaterials, a subsidiary of Pii, and professor at the London School of Pharmacy, told in-PharmaTechnologist.
Pharma companies are likely to be receptive to improved techniques. Buckton gave the example of amorphous formulations which were around for decades before being used frequently by industry.
“It’s become acceptable out of necessity I imagine”, Buckton said.